Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nymox obtains $15 million equity financing commitment
The funds will be used for general corporate purposes. The financing gives the company the right to place common stock to the investors at a 3% discount to
The funds will be used for general corporate purposes. The financing gives the company the right to place common stock to the investors at a 3% discount to
In addition, FDA has designated the submission for priority review, with a review goal date of April 30, 2009. Northfield had previously submitted the biologics license application (BLA)
AutoPulse is an automated, portable device with an easy-to-use, load-distributing LifeBand that squeezes the entire chest in an uninterrupted hands-free manner, improving blood flow to the heart and
Stavudine capsules, indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents, are the generic version of Bristol-Myers Squibb’s Zerit capsules. The product was shipped
The Phase II clinical trial is a multicenter, randomized, double-blind, placebo-controlled study assessing the analgesic efficacy and safety of T-62 in subjects with postherpetic neuralgia and its associated
According to the terms of Johnson & Johnson’s tender offer, shares that were validly tendered and not withdrawn have been accepted for payment. The tender offer expired on
In addition Novartis has an option to make an equity investment at the end of Phase II clinical trials for four million shares. Under the terms of the
Sosei has previously entered into a licensing agreement with Mundipharma, under which Mundipharma were granted the right to commercialize AD 923 in Europe and other international markets, excluding
Latisse is said to be the first science-based treatment approved by the FDA to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes.
Perrigo is expecting to begin product shipments to retailers during the first quarter of 2009. The product will be marketed under store brand labels and is comparable to